Physician profile
Daniel G Cameron
NPI 1558353987
$16,969.71
in general payments reported to CMS, 2019-2025
70 companies · $2,990 in 2025
The $2,990 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $1,077 · 2021: $1,896 · 2022: $3,021 · 2023: $3,265 · 2024: $3,658 · 2025: $2,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,649 · Education: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,649.49 |
| Education | $263.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,583.26 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,441.85 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| Merck Sharp & Dohme LLC | $1,144.89 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $1,076.47 | 2019-2025 | |
| Janssen Biotech, INC. | $903.00 | 2019-2025 | Erleada, Tecvayli, Balversa |
| Genentech USA, INC. | $872.64 | 2019-2025 | Tecentriq, Polivy, Phesgo |
| Incyte Corporation | $829.55 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Eisai INC. | $770.04 | 2020-2025 | |
| Amgen INC. | $723.07 | 2020-2023 | Kyprolis, Vectibix, Xgeva |
| E.R. Squibb & Sons, L.L.C. | $689.64 | 2020-2025 | Opdivo, Opdualag |
| Astellas Pharma US INC | $608.47 | 2019-2025 | Vyloy, Padcev, Xtandi |
| Celgene Corporation | $548.35 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Lilly USA, LLC | $488.75 | 2020-2025 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $434.46 | 2022-2025 | Libtayo, Lynozyfic |
| Daiichi Sankyo INC. | $354.65 | 2019-2025 | Enhertu, Datroway |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $281.51 | 2023-2025 | Orserdu |
| Glaxosmithkline, LLC. | $269.67 | 2020-2025 | Jemperli, Ojjaara |
| Exelixis INC. | $263.58 | 2022-2025 | Cabometyx |
| Abbvie INC. | $248.51 | 2019-2025 | Venclexta |
| Genzyme Corporation | $240.25 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $229.83 | 2022-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Gilead Sciences, INC. | $221.76 | 2021-2025 | Trodelvy |
| Blueprint Medicines Corporation | $163.00 | 2020-2025 | Ayvakit |
| Seagen INC. | $158.71 | 2021-2023 | Adcetris, Padcev |
| Pharmaessentia USA Corporation | $151.18 | 2024-2025 | Besremi |
| Beigene USA, INC. | $140.23 | 2022-2025 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $125.37 | 2022-2025 | Monoferric, Cosela |
| Deciphera Pharmaceuticals INC. | $116.10 | 2022-2025 | Qinlock, Romvimza, Tgct |
| Array Biopharma INC | $115.96 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.75 | 2023-2025 | Gilotrif |
| Emd Serono, INC. | $89.76 | 2022-2025 | Tepmetko |
| Adaptive Biotechnologies Corporation | $85.04 | 2023-2025 | Clonoseq |
| Sumitomo Pharma America, INC. | $78.59 | 2023-2025 | Orgovyx |
| Ethicon INC. | $78.12 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.42 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $72.29 | 2021-2024 | Ultomiris, Soliris |
| Agios Pharmaceuticals, INC. | $70.41 | 2023-2024 | Pyrukynd |
| Sobi, INC | $68.73 | 2023-2025 | |
| Beone Medicines USA, INC. | $68.19 | 2025 | Brukinsa |
| Tempus Ai, INC | $63.44 | 2024 | |
| Coherus Oncology, INC. | $60.01 | 2022-2025 | Udenyca |
| Tersera Therapeutics LLC | $59.51 | 2023-2025 | Zoladex, Quzyttir |
| Progenics Pharmaceuticals, INC. | $55.71 | 2022-2024 | Pylarify |
| Springworks Therapeutics, INC. | $53.25 | 2025 | Ogsiveo |
| Myovant Sciences INC. | $52.01 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $44.31 | 2022-2023 | Fotivda |
| Csl Behring | $42.22 | 2022-2023 | Hemgenix |
| Puma Biotechnology, INC. | $40.29 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $36.67 | 2024-2025 | Onivyde |
| Genmab U.S., INC. | $35.69 | 2024-2025 | Epkinly |
| Dendreon Pharmaceuticals LLC | $34.76 | 2024 | Provenge |
| Karyopharm Therapeutics INC. | $34.62 | 2023-2025 | Xpovio |
| Mirati Therapeutics, INC. | $32.69 | 2024 | Krazati |
| Rigel Pharmaceuticals, INC. | $31.10 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Adc Therapeutics America, INC. | $29.46 | 2021-2022 | |
| Servier Pharmaceuticals LLC | $27.42 | 2022 | |
| Janssen Scientific Affairs, LLC | $24.27 | 2023 | Tecvayli, Darzalex |
| Pharming Healthcare, INC. | $22.69 | 2023 | Ruconest |
| Morphosys, US INC. | $20.24 | 2023 | Monjuvi |
| Octapharma USA, INC. | $20.07 | 2022 | |
| Paratek Pharmaceuticals, INC. | $19.25 | 2021 | |
| Macrogenics, INC. | $18.74 | 2022 | |
| Novocure INC. | $18.17 | 2025 | Optune Lua (Novottf-200t) |
| Acrotech Biopharma INC. | $17.26 | 2025 | Beleodaq |
| Azurity Pharmaceuticals, INC. | $16.96 | 2025 | Danziten |
| Myriad Genetic Laboratories, INC. | $15.17 | 2024 | Myrisk |
| Apellis Pharmaceuticals, INC. | $14.62 | 2024 | Empaveli |
| Tactile Systems Technology INC | $13.35 | 2021 | |
| Clovis Oncology, INC. | $13.23 | 2022 | |
| Janssen Pharmaceuticals, INC | $3.48 | 2021 |
Drugs and devices associated with these payments
Keytruda $703Lynparza $465Lenvima $397Enhertu $384Opdivo $371Libtayo $335Reblozyl $300Imfinzi $298Verzenio $288Jaypirca $288Jakafi $285Orserdu $282Xtandi $264Kisqali $258Cabometyx $233Erleada $218Monjuvi $214Calquence $205Brukinsa $194Scemblix $189Tecvayli $178Tukysa $159Ibrance $159Inlyta $151Besremi $151Retevmo $145Tecentriq $139Adcetris $137Welireg $128Trodelvy $124Padcev $120Darzalex $119Akeega $118Balversa $118Venclexta $116Pomalyst $106Fabhalta $100Polivy $99.17Sarclisa $97.37Pemazyre $93.23Orgovyx $93.01Rybrevant $92.72Jemperli $92.55Qinlock $86.65Clonoseq $85.04Mektovi $84.75Braftovi $84.75Bosulif $83.87Elrexfio $82.19Talzenna $81.71Vyloy $80.86Ayvakit $78.54Ojjaara $73.12Imbruvica $71.39Pyrukynd $70.41Phesgo $69.83Pluvicto $67.86Tasigna $65.82Lunsumio $63.70Columvi $63.70Lorbrena $62.43Xalkori $62.43Talvey $58.46Ninlaro $57.84Epkinly $57.03Ogsiveo $53.25Monoferric $53.05Zynyz $48.70Udenyca $47.57Carvykti $44.37Comirnaty $44.00Elahere $43.89Vitrakvi $43.07Stivarga $43.07Nubeqa $42.26Opdualag $38.12Xospata $37.90Cosela $37.23Onivyde $36.67Pylarify $36.62Doptelet $36.16Promacta $36.15Zoladex $35.85Provenge $34.76Xpovio $34.62Romvimza $34.51Krazati $32.69Vonjo $32.57Enjaymo $32.47Cablivi $31.57Rezlidhia $31.10Tavalisse $31.10Datroway $29.67Gilotrif $28.51Xyntha $27.90Hympavzi $27.90Benefix $27.90Kyprolis $26.58Ultomiris $25.78Quzyttir $23.66
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cameron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.